[go: up one dir, main page]

WO2017106175A3 - Utilisation de stimulateurs de la sgc pour le traitement d'un dysfonctionnement du sphincter gastro-intestinal - Google Patents

Utilisation de stimulateurs de la sgc pour le traitement d'un dysfonctionnement du sphincter gastro-intestinal Download PDF

Info

Publication number
WO2017106175A3
WO2017106175A3 PCT/US2016/066357 US2016066357W WO2017106175A3 WO 2017106175 A3 WO2017106175 A3 WO 2017106175A3 US 2016066357 W US2016066357 W US 2016066357W WO 2017106175 A3 WO2017106175 A3 WO 2017106175A3
Authority
WO
WIPO (PCT)
Prior art keywords
sphincter
gastrointestinal
treatment
gastrointestinal tract
sgc stimulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/066357
Other languages
English (en)
Other versions
WO2017106175A2 (fr
Inventor
Kenneth E. Carlson
Joon Jung
Mark G. Currie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ironwood Pharmaceuticals Inc
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US16/061,992 priority Critical patent/US20180344735A1/en
Priority to CN201680078621.9A priority patent/CN108463224A/zh
Priority to JP2018531178A priority patent/JP2019502686A/ja
Priority to EA201891416A priority patent/EA201891416A1/ru
Priority to KR1020187019784A priority patent/KR20180094965A/ko
Priority to MX2018007152A priority patent/MX2018007152A/es
Priority to AU2016371762A priority patent/AU2016371762A1/en
Priority to EP16867373.9A priority patent/EP3389655A2/fr
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Priority to CA3006764A priority patent/CA3006764A1/fr
Publication of WO2017106175A2 publication Critical patent/WO2017106175A2/fr
Publication of WO2017106175A3 publication Critical patent/WO2017106175A3/fr
Priority to IL259639A priority patent/IL259639A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des procédés, utilisations, compositions pharmaceutiques et kits comprenant un stimulateur de la sGC ou un sel pharmaceutiquement acceptable de celui-ci, seul ou en combinaison avec un ou plusieurs agents thérapeutiques supplémentaires, pour le traitement d'un trouble du sphincter gastro-intestinal. Les troubles du sphincter gastro-intestinal comprennent, mais sans s'y limiter, une achalasie d'un sphincter du tractus gastro-intestinal, un sphincter spastique du tractus gastro-intestinal ou des spasmes du sphincter, ou un sphincter hypertendu du tractus gastro-intestinal.
PCT/US2016/066357 2015-12-14 2016-12-13 Utilisation de stimulateurs de la sgc pour le traitement d'un dysfonctionnement du sphincter gastro-intestinal Ceased WO2017106175A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2016371762A AU2016371762A1 (en) 2015-12-14 2016-12-13 Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction
JP2018531178A JP2019502686A (ja) 2015-12-14 2016-12-13 消化管括約筋機能障害の治療へのｓＧＣ刺激薬の使用
EA201891416A EA201891416A1 (ru) 2015-12-14 2016-12-13 ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА
KR1020187019784A KR20180094965A (ko) 2015-12-14 2016-12-13 위장 괄약근 기능장애의 치료를 위한 sGC 자극제의 용도
MX2018007152A MX2018007152A (es) 2015-12-14 2016-12-13 Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal.
US16/061,992 US20180344735A1 (en) 2015-12-14 2016-12-13 USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
CN201680078621.9A CN108463224A (zh) 2015-12-14 2016-12-13 sGC刺激剂用于胃肠功能障碍治疗的应用
EP16867373.9A EP3389655A2 (fr) 2015-12-14 2016-12-13 Utilisation de stimulateurs de la sgc pour le traitement d'un dysfonctionnement du sphincter gastro-intestinal
CA3006764A CA3006764A1 (fr) 2015-12-14 2016-12-13 Utilisation de stimulateurs de la sgc pour le traitement d'un dysfonctionnement du sphincter gastro-intestinal
IL259639A IL259639A (en) 2015-12-14 2018-05-28 Use of sgc stimulators to treat gastrointestinal sphincter dysfunction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562266988P 2015-12-14 2015-12-14
US62/266,988 2015-12-14

Publications (2)

Publication Number Publication Date
WO2017106175A2 WO2017106175A2 (fr) 2017-06-22
WO2017106175A3 true WO2017106175A3 (fr) 2017-10-19

Family

ID=58737844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/066357 Ceased WO2017106175A2 (fr) 2015-12-14 2016-12-13 Utilisation de stimulateurs de la sgc pour le traitement d'un dysfonctionnement du sphincter gastro-intestinal

Country Status (11)

Country Link
US (1) US20180344735A1 (fr)
EP (1) EP3389655A2 (fr)
JP (1) JP2019502686A (fr)
KR (1) KR20180094965A (fr)
CN (1) CN108463224A (fr)
AU (1) AU2016371762A1 (fr)
CA (1) CA3006764A1 (fr)
EA (1) EA201891416A1 (fr)
IL (1) IL259639A (fr)
MX (1) MX2018007152A (fr)
WO (1) WO2017106175A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017003518A (es) * 2014-09-17 2017-07-28 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
WO2017107052A1 (fr) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Activateurs solubles de guanylate cyclase
NZ753434A (en) 2016-11-08 2025-10-31 Tisento Therapeutics Inc Treatment of cns diseases with sgc stimulators
IL266372B2 (en) * 2016-11-08 2023-11-01 Cyclerion Therapeutics Inc Running SGC
US20190381039A1 (en) * 2016-12-13 2019-12-19 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS
MA53127A (fr) * 2018-07-11 2021-05-19 Cyclerion Therapeutics Inc Utilisation de stimulateurs gcs pour le traitement de maladies mitochondriales
US20240342187A1 (en) * 2021-06-14 2024-10-17 Curtails Llc Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders
JP2025515296A (ja) * 2022-04-20 2025-05-14 シャンハイ ジムン バイオファーマ，インコーポレーテッド Ｒｈｏ関連プロテインキナーゼ阻害剤ならびにその調製および応用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009014A1 (fr) * 1989-12-12 1991-06-27 Pfizer Limited Antagonistes de rectepteurs muscariniques
WO2002062324A2 (fr) * 2001-02-05 2002-08-15 Michael Albert Kamm Traitement des troubles de la motilite oesophagienne et du reflux gastro-oesophagien
WO2003080599A1 (fr) * 2002-03-26 2003-10-02 Novartis International Pharmaceutical Ltd. Hydrate stable d'antagoniste de recepteur muscarinique
RU2009135954A (ru) * 2009-09-28 2011-04-10 Иван Сергеевич Рагинов (RU) Способ лечения ахалазии пищевода
WO2014131760A1 (fr) * 2013-03-01 2014-09-04 Bayer Pharma Aktiengesellschaft Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante
WO2015106268A1 (fr) * 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. Utilisation de stimulateurs de la sgc pour le traitement de troubles neuromusculaires

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE59713007D1 (de) 1996-10-14 2009-06-25 Bayer Healthcare Ag Neue heterocyclylmethyl-substituierte pyrazolderivate und ihre verwendung in der behandlung von herz-kreislauf-erkrankungen
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
US6451805B1 (en) 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100720844B1 (ko) 1998-07-08 2007-05-25 사노피-아벤티스 도이칠란트 게엠베하 황 치환된 설포닐아미노카복실산 ｎ-아릴아미드, 이의 제조방법, 및 이를 함유하는 약제학적 제제
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19962926A1 (de) 1999-12-24 2001-06-28 Bayer Ag Verfahren zur Co-Mahlung von Stoffen und Lactose mittels Strahlmühlen
DE10021069A1 (de) 2000-04-28 2001-10-31 Bayer Ag Substituiertes Pyrazolderivat
DE10054278A1 (de) 2000-11-02 2002-05-08 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Osteoporose
DE10057754A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
AU2002221827A1 (en) 2000-11-22 2002-06-03 Bayer Aktiengesellschaft Novel lactame-substituted pyrazolopyridine derivatives
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10122894A1 (de) 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
DE10132416A1 (de) 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10222550A1 (de) 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
DE10232572A1 (de) 2002-07-18 2004-02-05 Bayer Ag Neue 2,5-disubstituierte Pyrimidinderivate
DE10232571A1 (de) 2002-07-18 2004-02-05 Bayer Ag 4-Aminosubstituierte Pyrimidinderivate
DE10242941A1 (de) 2002-09-16 2004-03-18 Bayer Ag Substituiertes Pyrazolderivat
DE10244810A1 (de) 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
DE102006020327A1 (de) 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
DE102006021733A1 (de) 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102006054757A1 (de) 2006-11-21 2008-05-29 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
JP5298129B2 (ja) 2007-09-06 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化因子
US8397065B2 (en) 2007-10-17 2013-03-12 Telcordia Technologies, Inc. Secure content based routing in mobile ad hoc networks
US7947664B2 (en) 2008-01-24 2011-05-24 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102009004245A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
WO2010099054A2 (fr) 2009-02-26 2010-09-02 Merck Sharp & Dohme Corp. Activateurs solubles de guanylate cyclase
PH12012501023A1 (en) 2009-11-27 2014-12-19 Adverio Pharma Gmbh Method for producing methyl - {4, 6-diamino -2-[1- (2-fluorobenzyl) -1h- pyrazolo [3,4-b] pyridino -3-yl] pyrimidino -5-yl} methyl carbamate and its purification for use thereof as pharmaceutical substance
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
MX2012006719A (es) 2009-12-14 2012-10-15 Bayer Ip Gmbh Solvatos de {4,6-diaminio-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b] piridin-3-il]pirimidin-5-il}carbamato de metilo nuevos.
WO2011115804A1 (fr) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Stimulateurs de sgc
EP2549875B1 (fr) 2010-03-25 2015-05-13 Merck Sharp & Dohme Corp. Activateurs de guanylate cyclase solubles
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
ES2549979T3 (es) 2010-05-26 2015-11-03 Adverio Pharma Gmbh El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS)
KR20140019004A (ko) 2010-05-27 2014-02-13 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
CN103313976B (zh) 2010-06-30 2016-11-23 铁木医药有限公司 sGC刺激物
AU2011275825A1 (en) 2010-07-09 2013-02-07 Bayer Intellectual Property Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
US8765769B2 (en) 2010-07-09 2014-07-01 Bayer Intellectual Property Gmbh Ring-fused 4-aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases
DE102010031667A1 (de) 2010-07-22 2012-01-26 Bayer Schering Pharma Aktiengesellschaft Substituierte Methyl-pyrimidin-5-ylcarbamate und ihre Verwendung
DE102010031665A1 (de) 2010-07-22 2012-01-26 Bayer Schering Pharma Aktiengesellschaft Substituierte Oxazolidinone und Oxazinanone und ihre Verwendung
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
WO2012058132A1 (fr) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Activateurs de la guanylate cyclase soluble
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
US9061030B2 (en) 2010-11-09 2015-06-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
WO2012152629A1 (fr) 2011-05-06 2012-11-15 Bayer Intellectual Property Gmbh Imidazopyridazines substituées et imidazopyridazines, et leur utilisation
EP2699578B1 (fr) 2011-04-21 2016-04-20 Bayer Intellectual Property GmbH Pyrazolopyridines substituées par un fluoro-alkyle et leur utilisation
DE102011075398A1 (de) 2011-05-06 2012-11-08 Bayer Pharma Aktiengesellschaft Substituierte Imidazopyridazine und ihre Verwendung
BR112013030909A2 (pt) 2011-05-30 2016-12-06 Astellas Pharma Inc compostos de imidazopiridina
EP2729476B1 (fr) 2011-07-06 2017-08-23 Bayer Intellectual Property GmbH Pyrazolopyridines hétéroaryl substituées et leur utilisation en tant que stimulateurs de la guanylate cyclase soluble
SG11201400083VA (en) 2011-09-02 2014-06-27 Bayer Ip Gmbh Substituted annellated pyrimidine and the use thereof
CU24354B1 (es) 2011-11-25 2018-08-06 Adverio Pharma Gmbh Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
CN102491974B (zh) 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
CA2861804C (fr) 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. Pyrazoles 2-benzyle, 3-(pyrimidin-2-yle)-substitues utiles comme stimulateurs de scg
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
WO2013131923A1 (fr) 2012-03-06 2013-09-12 Bayer Intellectual Property Gmbh Azabicyles substitués et leur utilisation
WO2014047111A1 (fr) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Stimulateurs de la sgc
EP2897953B8 (fr) 2012-09-19 2019-06-26 Cyclerion Therapeutics, Inc. Stimulateurs de sgc
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8778964B2 (en) 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
PL2927231T3 (pl) 2012-11-30 2018-01-31 Astellas Pharma Inc Związki imidazopirydyny
CA2901636A1 (fr) 2013-02-21 2014-08-28 Adverio Pharma Gmbh Formes du {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate de methyle
CN105026405B (zh) 2013-03-01 2017-08-08 拜耳制药股份公司 苄基‑取代的吡唑并吡啶及其用途
ES2966517T3 (es) 2013-03-15 2024-04-22 Cyclerion Therapeutics Inc Estimuladores de sGC
CN105339368B (zh) 2013-06-04 2017-08-15 拜耳制药股份公司 3‑芳基‑取代的咪唑并[1,2‑a]吡啶及其用途
CA2920565A1 (fr) 2013-08-08 2015-02-12 Bayer Pharma Aktiengesellschaft Pyrazolo[1,5-a]pyridine-3-carboxamides substitues et leur utilisation
CN106414440A (zh) 2013-12-05 2017-02-15 拜耳制药股份公司 芳基和杂芳基取代的咪唑并[1,2-a]吡啶-3-羧酰胺及其用途
CN106304835A (zh) 2013-12-11 2017-01-04 铁木医药有限公司 sGC刺激剂
EP3079700B1 (fr) 2013-12-11 2020-11-25 Merck Sharp & Dohme Corp. Activateurs solubles de guanylate cyclase
US9611278B2 (en) 2013-12-11 2017-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP2017507140A (ja) 2014-02-19 2017-03-16 バイエル・ファルマ・アクティエンゲゼルシャフト ３−（ピリミジン−２−イル）イミダゾ［１，２−ａ］ピリジン
CN106715426A (zh) 2014-03-21 2017-05-24 拜耳医药股份有限公司 氰基取代的咪唑并[1,2‑a]吡啶甲酰胺及其用途
EP3119778A1 (fr) 2014-03-21 2017-01-25 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridine-carboxamides substitués et leur utilisation
WO2015150366A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Dérivés d'éthers phénoliques à substitutions cycliques et leur utilisation
CA2944617A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Derives chiraux d'acide cyclopentanecarboxylique a disubstitution 2,5 et leur utilisation
WO2015150364A1 (fr) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Acides benzotriazinonebutyriques substitués et leur utilisation
US20170114049A1 (en) 2014-04-03 2017-04-27 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratory tract diseases
US20170022171A1 (en) 2014-04-03 2017-01-26 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentanecarboxylic acids and their use
WO2016044445A2 (fr) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Stimulateurs de sgc
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
WO2016044441A1 (fr) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Stimulateurs de la sgc
MX2017003518A (es) 2014-09-17 2017-07-28 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009014A1 (fr) * 1989-12-12 1991-06-27 Pfizer Limited Antagonistes de rectepteurs muscariniques
WO2002062324A2 (fr) * 2001-02-05 2002-08-15 Michael Albert Kamm Traitement des troubles de la motilite oesophagienne et du reflux gastro-oesophagien
WO2003080599A1 (fr) * 2002-03-26 2003-10-02 Novartis International Pharmaceutical Ltd. Hydrate stable d'antagoniste de recepteur muscarinique
RU2009135954A (ru) * 2009-09-28 2011-04-10 Иван Сергеевич Рагинов (RU) Способ лечения ахалазии пищевода
WO2014131760A1 (fr) * 2013-03-01 2014-09-04 Bayer Pharma Aktiengesellschaft Pyrimidines annelées à subsitution trifluorométhyle et utilisation correspondante
WO2015106268A1 (fr) * 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. Utilisation de stimulateurs de la sgc pour le traitement de troubles neuromusculaires

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Ironwood reports phase Ia data on soluble sGC stimulator IW-1701", 19 February 2016 (2016-02-19), XP002772858, Retrieved from the Internet <URL:https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_ref_list.xml_show_ficha_ref?p_ref_id=2464880> [retrieved on 20170808] *
ANONYMOUS: "Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type II Achalasia", 11 October 2016 (2016-10-11), XP002772859, Retrieved from the Internet <URL:https://clinicaltrials.gov/show/NCT02931565> [retrieved on 20170809] *
BAGCIVAN IHSAN ET AL: "Comparison of the effects of YC-1, DEA/NO, sodium nitroprusside and theophylline on the sheep sphincter of oddi", TURKIYE KLINIKLERI TIP BILIMLERI DERGISI,, vol. 25, no. 2, 1 January 2005 (2005-01-01), pages 161 - 166, XP009195196 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; WEISER, H. F. ET AL: "Clinical and experimental studies on the effect of nifedipine on smooth muscle of the esophagus", XP002772857, retrieved from STN Database accession no. 1979:48632 *
GIOVANNONI M P ET AL: "PDE5 Inhibitors and their Applications", CURRENT MEDICINAL CHEMISTRY : THE NEW INTERNATIONAL JOURNAL FOR TIMELY IN-DEPTH REVIEWS IN MEDICINAL CHEMISTRY, BENTHAM, NL, vol. 17, no. 24, 1 January 2010 (2010-01-01), pages 2564 - 2587, XP009195194, ISSN: 0929-8673 *
M GELFOND ET AL: "Effect of nitrates on LOS pressure in achalasia: a potential therapeutic aid.", GUT, vol. 22, no. 4, 1 April 1981 (1981-04-01), UK, pages 312 - 318, XP055397290, ISSN: 0017-5749, DOI: 10.1136/gut.22.4.312 *
MARKUS FOLLMANN ET AL: "The Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and Activators", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 52, no. 36, 20 August 2013 (2013-08-20), pages 9442 - 9462, XP055397554, ISSN: 1433-7851, DOI: 10.1002/anie.201302588 *
S BRULEY DES VARANNES ET AL: "Current trends in the management of achalasia", 1 January 2001 (2001-01-01), pages 266 - 277, XP055397078, Retrieved from the Internet <URL:http://ac.els-cdn.com/S1590865801807180/1-s2.0-S1590865801807180-main.pdf?_tid=ce3c91b8-7c3b-11e7-8e27-00000aacb35e&acdnat=1502198376_22f9bb50f84d33e4bf6d257fcd32d0f2> [retrieved on 20170808] *
SARAC, BULENT ET AL: "Investigation of Relaxant Effects of New Agents Affecting Nitric Oxide/Cyclic Guanosine Monophosphate Pathway on Sheep Oddi", PANCREAS (HAGERSTOWN, MD, UNITED STATES) , 39(6), 875-878 CODEN: PANCE4; ISSN: 0885-3177, 2010, XP009195190, DOI: 10.1097/MPA.0B013E3181D3645B 10.1097/MPA.0B013E3181D3645B *
ZIMMER DANIEL P ET AL: "The Soluble Guanylate Cyclase Stimulator IW-1701 Enhances Nitric Oxide-Mediated Relaxation of Human Lower Esophageal Sphincterex vivo", GASTROENTEROLOGY, ELSEVIER, US, 22 April 2017 (2017-04-22), XP085104333, ISSN: 0016-5085, DOI: 10.1016/S0016-5085(17)32443-5 *

Also Published As

Publication number Publication date
IL259639A (en) 2018-07-31
AU2016371762A1 (en) 2018-06-21
EP3389655A2 (fr) 2018-10-24
JP2019502686A (ja) 2019-01-31
CN108463224A (zh) 2018-08-28
CA3006764A1 (fr) 2017-06-22
US20180344735A1 (en) 2018-12-06
EA201891416A1 (ru) 2018-12-28
WO2017106175A2 (fr) 2017-06-22
MX2018007152A (es) 2018-08-15
KR20180094965A (ko) 2018-08-24

Similar Documents

Publication Publication Date Title
WO2017106175A3 (fr) Utilisation de stimulateurs de la sgc pour le traitement d&#39;un dysfonctionnement du sphincter gastro-intestinal
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
WO2016044189A8 (fr) Méthodes de traitement du cancer faisant appel à un antagoniste se liant à l&#39;axe pd-1 et à des antagonistes se liant à l&#39;il-17
MX2024002360A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
WO2016198932A3 (fr) Compositions de nanoparticules pour thérapie prolongée
WO2015121348A3 (fr) Composition pharmaceutique comprenant des érythrocytes encapsulant une enzyme dépendante du plp et son cofacteur
WO2017132432A8 (fr) Dérivés de benzimidazoles utilisés comme modulateurs de ror-gamma
EP4282479A3 (fr) Utilisation de pridopidine pour traiter la dépression ou l&#39;anxiété
WO2016172496A8 (fr) Inhibiteurs de lsd1 et leurs utilisations
WO2016044556A3 (fr) Inhibiteurs d&#39;arginine méthyltransférase et leurs utilisations
HK1199725A1 (en) Heterocyclic compounds and uses thereof
HK1206726A1 (en) Imidazotriazinone compounds
WO2015095834A3 (fr) Traitements du cancer faisant appel à des inhibiteurs des familles erk1/2 et bcl-2
WO2016109217A3 (fr) Inhibiteurs de la btk
TW201613578A (en) Pharmaceutical combinations
MX2017006437A (es) Compuestos espiroisoquinolin-1,4&#39;-piperidinicos con actividad multimodal contra el dolor.
PH12016502352A1 (en) Pharmaceutical composition
CA3010788A1 (fr) Procedes d&#39;administration de vasopresseurs
WO2016004413A3 (fr) Inhibiteurs de la gls1 pour le traitement de maladies
AU2019254701B2 (en) MIR-181 inhibitors and uses thereof
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
WO2017011356A3 (fr) Procédés et compositions pour traiter des maladies et des états induits par des médicaments
WO2018111795A3 (fr) Utilisation de stimulateurs de sgc pour le traitement de la motilité œsophagienne
WO2016106357A8 (fr) Combinaison d&#39;inhibiteurs de raf et d&#39;inhibiteurs de kinases aurora

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 259639

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 3006764

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/007152

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2018531178

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2016371762

Country of ref document: AU

Date of ref document: 20161213

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16867373

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 20187019784

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020187019784

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 201891416

Country of ref document: EA